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Abstract
The stiffness of cell membrane was found to be one of the factors determining resistance of a cell in vitro to antibiotic doxorubicin
action. Membranes of surviving cells are negatively charged (−35 – −30 mV) and have high values of stiffness (2.2–5.1 μРа) at the
doxorubicin concentrations in the medium of 1–500 μg/ml. If the drug concentration and exposure time are being increased, only cells
with ‘soft’ membrane (0.25–1 μРа) and positive surface potential (15–29 mV) survive. The data obtained have important prognostic
value in studying drug resistance of tumour blood cells and can be used as objective markers of efficiency of the antitumor therapy.
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Introduction
One of the challenges in modern oncohematology is the
search of mechanisms responsible for resistance of malignant
clones of hematopoietic system to a standard chemotherapy as
well as development of strategies for its inhibition. According
to statistical data ca. 10% of patients with acute myeloprolif-
erative processes in blood system demonstrate poor results of
initial standard chemotherapy and more than 60% of relapses
are resistant to a treatment (Siegel et al. 2014).
The use of anthracycline drugs, such as doxorubicin, is
widely spread in standard regimen of treatment of oncological
blood diseases. Despite a number of studies learning intracel-
lular molecular mechanisms of doxorubicin action (Bao et al.
2011; Denard et al. 2012; DiDonato et al. 2012; Du et al.
2012; Harati et al. 2012; Lerma-Díaz et al. 2006; Liu et al.
2008; Naci et al. 2012; Ortiz-Lazareno et al. 2014; Sun et al.
2011; Wang et al. 2012) so far there is no definite viewpoint
on how multiple drug resistance of tumour cells is developed.
We assume transport properties of biomembranes playing cru-
cial role in development of effective strategy to overcome drug
resistance. Several studies demonstrate a surface tension of bio-
membrane being decreased under the influence of doxorubicin
(Bell et al. 2013), which directly affects the intensity of endocy-
tosis and drug transfer into cell (Rauch and Farge 2000). From
the other hand, a vesicular transport of doxorubicin by endocy-
tosis strongly depends on biochemical composition and fluidity
of biomembranes. The increase of fluidity in chemoresistant tu-
mour cells was experimentally proved by Wheeler et al. (1982).
Thus, the mechanical properties of biological membrane signifi-
cantly determine its transport function, in particular, the ability of
drug to reach intracellular molecular targets. In other words, these
properties affect drug resistivity of a cell.
Taking this as a starting point, we became interested to shed
more light on how not only mechanical but also electrical prop-
erties of biomembranes influence drug resistivity of cell. The
particular task was to investigate elastic and electrical properties
of doxorubicin-resistant cell clones while lympho- and myelo-
proliferative processes are progressing in blood system.
Materials and methods
Cell cultivation Clones of tumour cells were obtained from
whole blood of patients with acute lymphoblastic (15 persons)
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and myeloblastic leucosis (5 persons) to be further referred to
as ALL and AML, respectively. The diagnosis for the patients
was established for the first time and no treatment was done.
The blood was venipunctured and was stored in vacuum vials
(Vacuette K3E). Then we centrifuged it at 1500 rpm (152 g)
for 5 min, washed off and re-suspended in RPMI-1640 medi-
um (PanEco, Russia).
Approximately 1 million of cells were seeded in 6-well
plates in RPMI-1640 medium in 1:1 cells-to-medium volume
ratio. Five wells were filled with doxorubicin solution
(Ebewe, Austria) in different concentrations (1, 10, 100, 500
and 1000 μg/ml) in a ratio of 1 μl of doxorubicin solution per
10 μl of cell suspension in RPMI-1640 medium. The sixth
well plate served as a control without addition of doxorubicin
solution. The cells were incubated for 1 h and 24 h at 37 °C in
a CO2 incubator.
The purpose of revealing the effect of doxorubicin on
biophysical properties of biomembranes determines the
choice of drug concentration. The range of concentra-
tions is therefore quite wide, exceeding the physiologi-
cal doses.
Assessment of viability was accomplished by coloration of
1 μl of cell suspension by 0.4% trypan blue solution in phos-
phate buffer (pH 7.2–7.3) and further calculation of dead cells
by means of light microscope (Olympus, USA). The percent-
age of surviving cells is given as:
N ¼ 1−number of stained cells
total number of cells
 
⋅100%
Doxorubicin-resistant cells were washed off thrice using
Hanks medium (pH 7.4) in order to remove the incubation
solution. Then we became able to study elastic and electric
properties of cell surface by means of various scanning modes
of atomic force microscope.
Atomic force microscopy Following to Skorkina et al.
(2015) we investigated elastic properties of blastic blood
forms using Integra-Vita instrument (configuration based
on inversed optical microscope Olympus IX-71 (NT-
MDT, Russia)) when applied a load of 25 local cell sur-
face regions (Fig. 1). 20 cells from each plate well were
scanned in semi-contact mode using NSG03 cantilevers
(Nanoworld, USA). Local Young’s modulus was calculat-
ed based on Sneddon’s modification of Hertzian contact
problem. Within the framework of this model, a cell is
assumed an elastic isotropic medium with a Poisson coef-
ficient ν = 0.5, and the cantilever needle is modeled by a
solid cone. The experimental curves were processed using
Ef3 software (NT-MDT, Russia).
Electrical properties of blasts were studied by measuring of
surface potential. Cell suspension was prepared according to a
protocol published by Sladkova and Skorkina (2014). Again,
20 cells from each plate well were scanned in Kelvin probe
mode using NSG03/TiN cantilevers (Nanoworld, USA)
with conductive titanium coating. The obtained scans
were further processed in Nova software (NT-MDT,
Russia).
Statistical data treatment Experimental results were treated
using variational statistics methods. All the data are given as
mean values along with their average standard errors.
Statistical analysis was accomplished with an aid of
Student’s t-criterion at p < 0.05.
Results
The results of incubation are shown in Figs. 2 and 3. The
fraction of viable blood cells for both types of acute leucosis
demonstrates monotonic decrease with increasing concentra-
tion of doxorubicin (Figs. 2 and 3).
After 1-h incubation of plate with ALL blood, the
fractions of viable cells have decreased almost two
and four times in comparison with control (doxorubicin
concentrations were 500 and 1000 μg/ml, respectively).
Also 97% and 24% of tumour lymphoblasts survived at
the drug concentrations of 1 μg/ml and 1000 μg/ml,
respectively. After 24-h incubation of ALL blood, the
fraction of doxorubicin-resistant cells has decreased in
similar way: 92% and 10% of tumour cell population
survived at the concentrations of doxorubicin of 1 μg/
ml and 1000 μg/ml, respectively (Fig. 2).
Blood cells from AML patients were found to be
more resistant to doxorubicin, particularly, to its high
doses. After 1-h and 24-h incubation, at least 55% and
40% of tumour myeloblasts, respectively, maintained
their viability despite even the highest concentration of
doxorubicin (Fig. 3).
The viability of tumour cells is closely related to their func-
tional activity; therefore, we measured surface potential of
doxorubicin-resistant cell membranes. No reliable changes
of biomembrane charge was detected at the doxorubicin con-
centration of 1 μg/ml (Table 1). After 1-h incubation of ALL
blood, 8%, 38% and 91% (p < 0.05) decrease of surface po-
tential in resistant populations of tumour cells were observed
at the drug concentrations of 10, 100 and 500 μg/ml, respec-
tively. At the highest drug concentration of 1000 μg/ml
doxorubicin-resistant cells have lost negative charge and their
surface potential have been essentially increased. After 24-h
incubation, similar phenomena were observed. However, at
the drug concentration of 500 μg/ml it was detected 40%
(p < 0.05) increase of surface potential of resistant cells. At
the concentration of 1000 μg/ml the charge of surviving cells
increased by 85% (p < 0.05) as compared with the charge of
cells after 1-h incubation.
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The properties of surviving AML blood cells under the
influence of doxorubicin were found to be similar to those of
ALL blood cells. Surface potentials of cell membranes have
decreased after 1-h incubation in the concentration range of
100–500 μg/ml. The most significant decrease by 97%
(p < 0.05) has been detected at the drug concentration of
500 μg/ml. In the samples with 1000 μg /ml of doxorubicin
cell membranewas positively charged (see Table 1). After 24-h
incubation, similar phenomena was observed: positive charge
of membranes of doxorubicin-resistant cells at 1000 μg/ml
drug concentration had increased by 68% (p < 0.05) as com-
pared with charge of cells after 1-h incubation.
Not only electrical, but also elastic properties of cell surface
were studied for doxorubicin-resistant cells. After 1-h incuba-
tion, in the samples from ALL patients the average stiffness of
cell surface has increased by 26%, 95% and 189% (p < 0.05)
at the drug concentrations of 10, 100 and 500 μg/ml, respec-
tively. However, at the highest concentration of 1000 μg/ml in
the rest population of doxorubicin-resistant cells the stiffness
of cell surface has decreased by 67% (p < 0.05) (see Table 2).
After 24-h incubation the doxorubicin-resistant cells were
found having stiffness significantly lower than that of the con-
trol values (see Table 2).
For AML blood we observed the similar picture as for ALL
blood after 1-h incubation. The stiffness of cell surface has
increased by 42%, 74% and 94% (p < 0.05) in the drug con-
centration range of 10, 100 and 500 μg/ml, respectively.
However, at the concentration of 1000 μg/ml the cell stiff-
nesses have decreased by 45% and 86% (p < 0.05) after 1-h
and 24-h incubation, respectively (see Table 2).
Fig. 1 Local points of force apposition on cell surface
Fig. 2 The fraction of doxorubicin-resistant cells from patients with acute
lymphoblastic leucosis
Fig. 3 The fraction of doxorubicin-resistant cells from patients with acute
myeloblastic leucosis
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Discussion
Drug resistance of tumour cell is defined by the properties of
its membrane as well as molecular weight of a drug which is
crucial for development of drug resistance (Rauch 2008). We
detected doxorubicin-resistant leukemic cell clones of
lympho- and myeloblastic types of proliferation. The most
resistant to the drug are myeloblastic forms. Among them
ca. 40% of tumour cells preserve their viability even after
24-h incubation in the medium with the highest drug
concentration.
At the relatively low concentrations of doxorubicin quite
high percentage (50–95%) of surviving cells maintains high
values of stiffness and negative charge of membrane. This
indicates that primarily the drug enters a cell by means of
diffusion which was modelled earlier (Dalmark and
Hoffmann 1983; Skovsgaard and Nissen 1982). Drug passage
through a membrane leads to death of less than 4–6% of leu-
kemic clones partly differentiated in cell cycle.
However, on increasing both drug concentration and
incubation time the cell membrane becomes softer, and the
charge of cell surface increases gradually, reaching positive
values at the highest concentrations of doxorubicin. This is
due to the high affinity of doxorubicin to a lipid bilayer of
membrane. According to Bell et al. (2013) used model cell
lines, doxorubicin decreases the difference of surface tension
between lipid layers in the membrane, but does not change
surface potential of cell. Our experimental results show the
change of surface potential of leukemic clones.
At the high drug concentrations, cells maintained their
therapy-resistance and acquired both positive charge of cell
surface and a very soft cell membrane. The mechanism of this
survival, probably, lies in changing the mechanical properties
of membranes and/or the work of membrane transporters un-
der the influence of high doses of doxorubicin. According to
Hurwitz et al. (1997) the drug molecules are accumulated in
lysosomes which are involved in the formation of drug resis-
tance of myeloid cells. In turn, the formation of lyso-
somes can be related to the change of membrane curva-
ture (Rauch and Farge 2000). Thus, we explain the
change of the elastic properties of cell membranes by
the existence of additional bends caused by formation of
lysosomes to accumulate doxorubicin.
Another explanation is that doxorubicin molecule changes
flow properties of cell membrane being highly affined to its
lipids and thereby affecting the work of membrane trans-
porters. It is known that drug molecule can influence mem-
brane transporters via changing the membrane stiffness
(Rauch et al. 2013). Possibly, the change of both cell
membrane charge and its elastic properties under the in-
fluence of doxorubicin relate to the drug uptake by mem-
brane. Despite its hydrophobicity, doxorubicin facilitates
Table 1 The value of the surface
potential (mV) of the
doxorubicin-resistance cells
Samples Acute lymphoblastic leucosis Acute myeloblastic leucosis
1 h 24 h 1 h 24 h
Control −28.36 ± 0.12 −24.18 ± 0.10
1 μg/ml −26.71 ± 0.34 −29.36 ± 0.38 −24.65 ± 0.19 −27.53 ± 0.26
10 μg/ml −30.71 ± 0.25* −35.82 ± 0.17* −29.33 ± 0.24* −33.12 ± 0.08*
100 μg/ml −39.18 ± 0.71* −51.27 ± 0.24* −35.21 ± 0.04* −40.18 ± 0.19*
500 μg/ml −54.22 ± 1.13* −11.23 ± 0.22* −47.63 ± 0.12* −59.71 ± 0.36*
1000 μg/ml 15.76 ± 2.19* 29.18 ± 0.27* 12.37 ± 0.07* 20.81 ± 0.21*
*Statistically reliable differences in experiment in comparison with control at p < 0.05
Table 2 The elastic properties of
the doxorubicin-resistance cells
(μPa)
Samples Acute lymphoblastic leucosis Acute myeloblastic leucosis
1 h 24 h 1 h 24 h
Control 1.783 ± 0.001 1.854 ± 0.001
1 μg/ml 1.842 ± 0.002 1.712 ± 0.001 1.872 ± 0.001 1.835 ± 0.001
10 μg/ml 2.245 ± 0.001* 1.385 ± 0.002* 2.620 ± 0.001* 2.057 ± 0.001*
100 μg/ml 3.472 ± 0.002* 1.210 ± 0.002* 3.212 ± 0.001* 2.240 ± 0.002*
500 μg/ml 5.140 ± 0.001* 0.905 ± 0.001* 3.585 ± 0.001* 1.847 ± 0.002
1000 μg/ml 0.582 ± 0.001* 0.397 ± 0.001* 1.027 ± 0.001* 0.252 ± 0.001*
*Statistically reliable differences in experiment in comparison with control at p < 0.05
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water transport into a cell through polar groups of phos-
pholipids in biomembrane. Particularly, doxorubicin mol-
ecule contributes to the distortion of a membrane and,
therefore, water penetration into a cell while attracting
dipalmitoyl phosphatidylcholine headgroups (Yacoub
et al. 2011). The analysis of literature suggests that mul-
tidrug cell resistance of patients with acute forms of
leucosis is associated with expression and mutation of ATP
binding cassettes in cell membrane. The functional activity of
ATP binding cassettes changes after the use of anthracyclines
in the therapeutic schemes (Sehgal et al. 2015). A number of
studies show the chemotherapeutic resistance of tumour cells
being related to the existence of transport pump P-
glycoprotein in the membrane which actively removes the
drug from cell (Aller et al. 2009; Rauch et al. 2013).
Conclusions
Tumour cells resistance to doxorubicin is initially
formed at membrane level. The stiffness and the charge
of cell surface are the objective criteria indicating the
resistance of tumour cells to a therapy. The positive
charge of membrane and ‘soft’ cell surface are the char-
acteristic properties of the membranes of antibiotic-
resistant leukemic cell clones. These biomechanical
properties allow cells to maintain a high degree of ma-
lignancy, and proliferative and invasive potentials. In
circulation system blood cells are able to attract to neg-
atively charged vascular endothelium and quickly mi-
grate into tissues thereby providing there metastasis
and formation of foci of proliferation. This is due to
the detected unique membrane properties possessed un-
der the influence of doxorubicin.
The data obtained have important clinical and diag-
nostic value in the therapeutic treatment and the disease
prognosis. The electrical and mechanical properties of
the surface of tumour cells are of paramount importance in
the prediction of drug resistance and can be used as the objec-
tive markers of functional state of leukemic clones.
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